U.S. Food & Drug Administration
Baseline protease genotype affects HIV response to atazanavir/ritonavir
Published in AIDS Weekly and Law, June 8th, 2006
Researchers in the United States conducted a study "to assess the virologic response rates of atazanavir/ritonavir and lopinavir/ritonavir based on baseline genotype and phenotype."
"Resistance analyses were performed on a Bristol-Myers Squibb-sponsored study comparing the safety and efficacy of atazanavir/ritonavir to lopinavir/ritonavir in treatment-experienced subjects at 48 weeks," explained Lisa K. Naeger and Kimberly A. Struble at the U.S. Food and Drug Administration. "Analyses evaluated virologic response based on the presence of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
Source: AIDS Weekly and Law (2006-06-08)
More Articles from AIDS Weekly and Law
- Advanced BioScience Laboratories, Inc.
ALVAC-HIV-1/protein boost vaccine strategy reduces SHIV RNA levels - Chembio Diagnostics, Inc.
Chembio supports CDC's recommendation for routine HIV testing - French National Institute of the Recherche Agronomique
Amino acid-glucose infusion improves leucine imbalance in PI-treated HIV/AIDS patients - Advanced BioScience Laboratories
Studies from the United States and United Kingdom describe new findings in HIV/AIDS research - AIDS Research Center, Palo Alto
Hepatitis C virus protease gene diversity exists in HIV coinfection - Attikon University General Hospital, Athens
Lopinavir-ritonavir associated with significant hypertriglyceridemia - More from this issue of AIDS Weekly and Law
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
